Skip to main content
Condition

Chronic Pain: A Neurological Approach

Chronic pain that persists beyond tissue healing is not a musculoskeletal problem. It is a neurological one. When the central nervous system learns to amplify, sustain, and generate pain signals independent of peripheral input, the diagnosis belongs in neurology—and so does the treatment. We evaluate chronic pain as a disorder of the brain and spinal cord, not as a billing code for more injections.

Central Sensitization: When the Brain Becomes the Pain Generator

In a healthy nervous system, pain is a proportional response to a noxious stimulus. Tissue damage activates peripheral nociceptors, the signal travels through the dorsal horn of the spinal cord, and the brain registers the experience at a level that matches the severity of the input. When the injury heals, the signal stops. That is how the system is supposed to work.

Central sensitization is what happens when it doesn’t. In this state, the dorsal horn neurons become hyperexcitable. NMDA receptors upregulate, lowering the threshold for activation. Wind-up occurs—a progressive increase in action potential firing from repeated C-fiber input that leaves second-order neurons in a state of sustained depolarization. The result is pain that persists after the peripheral stimulus has resolved, pain that spreads beyond the original injury site, and pain triggered by stimuli that should not hurt at all.

Clifford Woolf described this mechanism in his landmark 2011 review in Pain, identifying central sensitization as a distinct clinical entity driven by altered synaptic processing in the spinal cord and brain. Latremoliere and Woolf (2009, The Journal of Pain) further characterized the molecular cascades involved: phosphorylation of NMDA and AMPA receptor subunits, activation of intracellular kinase pathways including PKC and ERK, and loss of GABAergic and glycinergic inhibitory tone in the dorsal horn. These are not abstract laboratory findings. They explain why a patient’s MRI can look normal while their experience of pain is devastating.

Descending inhibition failure compounds the problem. Under normal conditions, brainstem nuclei—the periaqueductal gray, the rostral ventromedial medulla—send inhibitory signals down the spinal cord that modulate incoming pain transmission. In centrally sensitized patients, this top-down brake weakens or reverses, allowing pain signals to pass through the dorsal horn with less filtering. The patient doesn’t just feel more pain. Their nervous system has lost the capacity to turn the volume down.

This is why opioids fail in central sensitization. Opioids act primarily on mu receptors in the peripheral and central nervous system to suppress nociceptive transmission. But when pain is being generated by NMDA-driven synaptic plasticity and disinhibited spinal circuits, mu-receptor agonism does not address the mechanism. Escalating opioid doses in these patients produces tolerance and dependence without resolving the underlying neuroplastic changes that maintain the pain state.

CRPS and Neuroinflammatory Pain

Complex regional pain syndrome is among the most severe chronic pain conditions a neurologist encounters. It typically develops after an injury—a fracture, a surgery, a soft tissue trauma—and presents with pain that is wildly disproportionate to the inciting event. The affected limb may show edema, color changes, temperature asymmetry, trophic changes to the skin and nails, and motor dysfunction. In advanced cases, the pain spreads to contralateral limbs or becomes generalized.

The Budapest criteria, codified by Harden et al. (2010, Pain Medicine), established the current diagnostic framework for CRPS. Diagnosis requires continuing pain disproportionate to the inciting event, plus signs and symptoms across at least three of four categories: sensory (allodynia, hyperalgesia), vasomotor (temperature or color asymmetry), sudomotor/edema (swelling, sweating changes), and motor/trophic (weakness, tremor, dystonia, skin or nail changes). The criteria were designed to balance sensitivity and specificity, but in practice, CRPS remains underdiagnosed because many clinicians are unfamiliar with the full spectrum of its presentation.

The pathophysiology of CRPS involves a convergence of peripheral and central mechanisms. Neurogenic inflammation mediated by substance P and CGRP produces the vasomotor and sudomotor changes. Sympathetic-afferent coupling creates a loop in which sympathetic nervous system activity drives nociceptor activation. And central sensitization, the same NMDA-driven process described above, amplifies and sustains the pain signal long after the original injury has healed. Autoimmune mechanisms have also been implicated: antibodies against autonomic nervous system receptors have been identified in a subset of CRPS patients, suggesting that the immune system can directly attack the neural infrastructure that regulates blood flow and pain in the affected limb.

Evaluating CRPS properly requires a neurologist who understands both the peripheral and central components. Treating only the limb while ignoring the brain’s role in maintaining the pain state is why so many CRPS patients cycle through nerve blocks, sympathectomies, and spinal cord stimulators without meaningful relief.

Why Standard Pain Management Falls Short

The typical pain clinic operates on a procedural model. Patients arrive with pain. They receive an MRI of the relevant spine segment. If a structural abnormality is found, an injection is offered. If the injection fails, a different injection is tried, or a stimulator is discussed, or opioids are prescribed at escalating doses. The neurological workup that should precede any of these interventions is rarely performed.

This model works for acute, nociceptive pain with a clear structural generator—a herniated disc pressing on a nerve root, an inflamed facet joint, a torn rotator cuff. It fails badly when the pain is being driven by central sensitization, neuroinflammation, autonomic dysfunction, or post-traumatic neuroplastic changes. In those cases, the MRI may be unremarkable, the injections may provide only days of relief, and the patient is gradually reclassified as a chronic pain patient who “needs to manage expectations.”

The missing step is the neurological evaluation. No one has assessed whether the dorsal horn is hyperexcitable. No one has tested descending inhibition. No one has measured whether the patient’s pain thresholds have shifted in a pattern consistent with central sensitization. No one has checked autonomic function for the sympathetic dysfunction that drives CRPS. Without these data, every treatment is empirical—a guess informed by anatomy rather than by the actual mechanism producing the pain.

Post-concussive persistent pain deserves particular attention in this context. Patients with traumatic brain injury frequently develop chronic headaches, neck pain, and widespread body pain that does not respond to the musculoskeletal interventions their primary care doctors prescribe. The reason is straightforward: the pain is neurological. It is generated or amplified by injured cortical and brainstem circuits, not by damaged muscles or joints. Treating these patients in a pain clinic without a concurrent neurological evaluation is treating the symptom while ignoring the organ that produces it. Learn more about our approach to brain injury on our traumatic brain injury page.

Our Diagnostic Approach

Before we treat chronic pain, we identify the mechanism producing it. Each diagnostic tool answers a specific question about where the signal is being generated or amplified.

Advanced Neuroimaging

Functional MRI and PET scanning reveal pain-processing abnormalities that structural imaging misses. We assess cortical thickness in somatosensory and insular cortex, connectivity between the pain matrix and prefrontal regulatory regions, and metabolic activity in brainstem pain-modulation centers.

Quantitative Sensory Testing

QST maps thermal and mechanical detection and pain thresholds across dermatomes. Shifted thresholds and temporal summation patterns provide objective evidence of central sensitization and help distinguish neuropathic from nociceptive pain mechanisms in patients with ambiguous presentations.

Autonomic Testing

Sympathetic skin response, heart rate variability, and sudomotor testing evaluate the autonomic nervous system dysfunction that drives vasomotor and trophic changes in CRPS and that contributes to pain amplification through sympathetic-afferent coupling.

Inflammatory & Neuroinflammatory Panels

Blood panels measuring high-sensitivity CRP, IL-6, TNF-alpha, and neurofilament light chain identify systemic and neuroinflammatory contributions to the pain state. These markers guide anti-inflammatory components of the treatment protocol and provide objective measures for tracking response over time.

Frequently Asked Questions

How is a neurological approach to chronic pain different from a pain clinic?+
Most pain clinics focus on interventional procedures and opioid management without investigating the neurological origin of the pain. Our evaluation starts with the nervous system. We use advanced neuroimaging, quantitative sensory testing, and autonomic studies to determine whether the pain is being driven by central sensitization, peripheral nerve dysfunction, neuroinflammation, or disrupted descending inhibition. The treatment plan follows from those findings rather than from a protocol applied uniformly to every patient.
What conditions do you treat under chronic pain?+
We evaluate and treat complex regional pain syndrome (CRPS), central sensitization syndromes, persistent post-concussive pain, trigeminal and occipital neuralgia, neuropathic pain with neurological features, and chronic pain that has not responded to standard interventional or pharmacological management. If pain is being generated or amplified by the central nervous system rather than by ongoing tissue injury, it falls within our scope.
What diagnostic tests do you use for chronic pain evaluation?+
Our workup includes functional neuroimaging to assess cortical pain processing, quantitative sensory testing to map threshold changes in pain and temperature perception, autonomic testing to evaluate sympathetic nervous system function, and blood panels for inflammatory and neuroinflammatory markers. These tests identify where the pain signal is being generated or amplified, which determines which therapies will be effective.
Do you prescribe opioids for chronic pain?+
No. Our approach is designed to treat the neurological source of chronic pain, not to mask it pharmacologically. We use nerve blocks for specific peripheral generators, and neurocoaching to address the behavioral and cognitive dimensions of chronic pain. These therapies target the mechanisms that maintain the pain state rather than suppressing the signal at the receptor level.
How long does the chronic pain evaluation take?+
The initial evaluation is delivered through our Intensive Brain Health Program over three to five consecutive days. Patients undergo diagnostic testing, a detailed review of findings with Dr. Orr, and begin their treatment protocol during that window. Follow-up visits for ongoing neuromodulation or infusion therapy are scheduled based on individual response and the complexity of the pain condition.
Does insurance cover neurological chronic pain treatment?+
The Neurogenesis Project operates outside of insurance networks. Our diagnostic and treatment protocols use therapies that are not typically covered by commercial insurance or Medicare. We provide detailed superbills and medical documentation that patients can submit for potential out-of-network reimbursement. Our patient coordinator can discuss costs and documentation options before you schedule.

Chronic Pain Deserves a Neurological Workup

If you’ve been through pain clinics, opioid tapers, and injections that don’t hold—the problem may not be where anyone has been looking. Dr. Orr evaluates chronic pain as a disorder of the central nervous system and builds a treatment plan around what the diagnostics actually show. The Neurogenesis Project is accepting new patients in St. Marys, Georgia.